Cargando…
Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
A 73-year-old Japanese man was histologically diagnosed with lung adenocarcinoma harboring an exon 19 deletion in the epidermal growth factor receptor. The patient was treated with gefitinib for 6 weeks until he developed substantially elevated hepatic enzyme levels that resulted in the discontinuat...
Autores principales: | Nagano, Tatsuya, Kotani, Yoshikazu, Kobayashi, Kazuyuki, Katsurada, Masahiro, Hatakeyama, Yukihisa, Hori, Suya, Tamura, Daisuke, Kasai, Daisuke, Funada, Yasuhiro, Nishimura, Yoshihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420486/ https://www.ncbi.nlm.nih.gov/pubmed/22937431 http://dx.doi.org/10.1155/2011/812972 |
Ejemplares similares
-
Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005) -
Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012) -
Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013) -
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005) -
Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)